Baosheng Media Gr (NASDAQ:BAOS) Stock, Quote.Headers.trade-ideas

Baosheng Media Gr

Baosheng Media Group Holdings Ltd operates as a V-log streaming marketing service provider. The firm offers comprehensive marketing solutions. Its services are Internet effect marketing, V-log or short video streaming marketing including content production and operation, e-commerce marketing, original big data platform system service, and AI technology. It provides one-stop and full-link deep customized marketing solutions for partners. Baosheng Group is also a core agency of domestic Internet companies such as Tencent, Alibaba, Bytedance, and Kuaishou, with performing channel marketing services, technologies, and applications.

Movers

News

Pre-Market Outlook

Markets

Trading Ideas

AGRI

BAOS

BITF

CGBS

CPOP

DATS

EAST

GPAK

LTRY

MSTR

PETZ

PHUN

Qualigen Therapeutics, Inc. - Common Stock

QLGN

VNCE

Why Trump Media &amp; Technology Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Intraday Update

AISP

AMPE

ARQT

ATUS

BACK

BBLG

BETS

BJDX

BLIN

CALT

CING

Envoy Medical, Inc. - Class A Common Stock

COCH

CTSO

CYTH

DOYU

EFSH

EGOX

ESPR

FLUX

FWBI

HALL

IOVA

IREN

LAES

LGCB

LIDR

MBOT

MHUA

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

NVFY

OCEA

RNXT

SIDU

SNES

SNTG

TIGR

WULF

Shares of  DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program.

Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

ACNT

ARBB

ASST

BCLI

CHRS

COIN

CYTK

ELTX

EWTX

GDHG

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

JTAI

JZXN

MGAM

MOBX

MTNB

MYND

NUKK

ONCT

ORGO

RPHM

SMFL

VLCN

VRAX

Shares of  Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per share.

Reneo Pharmaceuticals shares climbed 13.6% to $1.59 on Wednesday.

Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Baosheng Media Group Holdings Limited - Ordinary shares

Baosheng Media Group Holdings Ltd

<p><strong>Orgenesis Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) shares are trading lower by 21% to 40 cents during Monday&#8217;s session after the company announced that its Board of Directors has approved a <a href="https://www.benzinga.com/pressreleases/24/09/g40976804/orgenesis-announces-reverse-stock-split">1-for-10 reverse stock split</a>, effective at 5:00 pm ET on September 24.</p>
<p>Orgenesis says this move aims to meet Nasdaq&#8217;s minimum $1.00 bid price requirement. The stock will continue trading under the symbol &#8220;ORGS&#8221; on a split-adjusted basis starting September 25. </p>
<p>The reverse split will reduce the number of outstanding shares from 47.7 million to approximately 4.77 million, while stockholders&#8217; ownership percentages remain unchanged. </p>
<p>The company also announced that fractional shares will be paid out in cash based on the closing price on September 24.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">Qualcomm Takeover Of Intel Is &#8216;Logically Unlikely&#8217; In Face Of Regulatory Challenges, Analyst Says</a></strong></p>
<h2 class="wp-block-heading">Should I Sell My ORGS Stock?</h2>
<p>When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.</p>
<p>Shares of Orgenesis have decreased by 29.34% in the past year. An investor who bought shares of Orgenesis at the beginning of the year would take a loss of $0.05 per share if they sold it today. The stock has fallen 37.67% over the past month, meaning an investor who bought shares on Aug. 1 would see a capital loss of $0.33.</p>
<p>Orgenesis shares have an all-time high of $5.02, representing 1045.86% upside from current levels.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ORGS has a 52-week high of $1.08 and a 52-week low of $0.25.</p>


ORGS

Why Orgenesis (ORGS) Stock Is Down 23% Today

<p><strong>Masimo</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/masi#NASDAQ">MASI</a>) shares soared 8.7% in the last trading session to close at $121.42. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock&#39;s 8.5% loss over the past four weeks.</p>
<p>The sharp upsurge in Masimo&#39;s shares can be attributed to the surprising news regarding the company&#39;s newly elected Board of Directors. On Sept. 19, per a public statement issued from Politan, activist investor Quentin Koffey, and his Politan Capital Management group&#39;s proposed candidates, both won election to the two available Board seats of Masimo. This guarantees that the new independent directors now have a control of the Board. On Sept. 20, the share price of MASI surged as the investors continued to celebrate the news in a positive view that the new Board is likely to be more conscious of and responsive to the investors.</p>
<p>This medical technology company is expected to post quarterly earnings of $0.84 per share in its upcoming report, which represents a year-over-year change of +33.3%. Revenues are expected to be $501.93 million, up 4.8% from the year-ago quarter.</p>
<p>While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.</p>
<p>For Masimo, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock&#39;s price usually doesn&#39;t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MASI going forward to see if this recent jump can turn into more strength down the road.</p>
<p>The stock currently carries a Zacks Rank #2 (Buy).</p>
<p>Masimo is part of the Zacks Medical - Instruments industry. <strong>CVRx</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvrx#NASDAQ">CVRX</a>), another stock in the same industry, closed the last trading session 1.5% lower at $9.11. CVRX has returned 10.9% in the past month.</p>
<p>For CVRx, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.45. This represents a change of -4.7% from what the company reported a year ago. CVRx currently has a Zacks Rank of #3 (Hold).</p>
<p><a href="https://www.zacks.com/stock/news/2339653/masimo-masi-surges-8-7-is-this-an-indication-of-further-gains?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_3%-2339653">To read this article on Zacks.com click here.</a></p>


Earnings

Mid Cap

Health Care

Analyst Ratings

Tech

General

CVRX

MASI

Masimo Surges 8.7%: Is This an Indication of Further Gains?

<p><strong>Wells Fargo &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares are trading lower by 2.0% to $55.17 Monday afternoon. The stock is pulling back after rallying last week following the news of the <strong>Federal Reserve&#8217;s</strong> unexpected <a href="https://www.benzinga.com/markets/equities/24/09/40965372/fed-delivers-large-interest-rate-cut-in-bid-to-sustain-labor-market-stocks-gold-set-new-record-h">50-basis-point rate cut</a>.</p>
<p>Wells Fargo&#8217;s sensitivity to interest rate changes and investor speculation about the short-term effects on profitability has caused the stock to be volatile in recent sessions. </p>
<p><strong>What Happened:</strong> Last week&#8217;s larger-than-expected cut lowered the federal funds rate to a range of 4.75% to 5%, which was perceived as a positive development for Wells Fargo. Banks like Wells Fargo typically benefit from lower short-term borrowing costs, as they can access cheaper funding and potentially increase their net interest margins in the near term. </p>
<p>Additionally, lower interest rates tend to stimulate borrowing by consumers and businesses, which could lead to increased loan demand and higher interest income for Wells Fargo. This potential for immediate growth in lending and profitability likely contributed to the stock&#8217;s initial rise, as investors anticipated a more favorable environment for the bank.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/insights/options/24/09/40985016/what-the-options-market-tells-us-about-wells-fargo">What The Options Market Tells Us About Wells Fargo</a></strong></p>
<p>Furthermore, the Federal Reserve&#8217;s statement that inflation was moving sustainably toward 2% added to the market's confidence. As inflation concerns eased, the economic outlook seemed more stable, which would benefit Wells Fargo's business, as consumer and business confidence is critical for maintaining strong lending activity. </p>
<p>The prospect of additional rate cuts, as indicated by the Fed's dot plot, suggested a longer period of easier monetary policy, further fueling the short-term enthusiasm for Wells Fargo stock.</p>
<p><strong>What Else:</strong> Monday&#8217;s subsequent pullback could reflect a more cautious reassessment of the bank&#8217;s long-term outlook. Although lower interest rates reduce short-term borrowing costs, they also typically lead to a decline in long-term rates. This could compress Wells Fargo&#8217;s net interest margins, as the bank earns less on long-term loans while still facing lower yields on its assets. </p>
<p>Over time, the bank&#8217;s ability to generate income from interest on loans could be hampered in a prolonged low-rate environment, reducing profitability. Investors likely became concerned that while the initial rate cut seemed positive, the extended path of rate reductions might hurt Wells Fargo's ability to sustain its earnings over the longer term.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40983043/us-services-growth-tops-estimate-contraction-in-manufacturing-worsens-reacceleratio">US Services Growth Tops Estimate, Contraction In Manufacturing Worsens: &#8216;Reacceleration Of Inflation&#8217;</a></strong></p>
<p>Additionally, the Federal Reserve's updated economic projections painted a less favorable picture for future growth. The downward revision in real GDP growth forecasts, coupled with higher unemployment projections through 2026, signaled a weakening economy. </p>
<p>This raised concerns about potential loan defaults, as higher unemployment often leads to increased credit risk. Wells Fargo, which holds large portfolios of consumer and business loans, could face rising delinquencies and losses in a slower economy. </p>
<p>The bank&#8217;s exposure to consumer credit, mortgages and commercial loans means that an economic downturn or a prolonged period of sluggish growth would directly impact its earnings.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40983043/us-services-growth-tops-estimate-contraction-in-manufacturing-worsens-reacceleratio">US Services Growth Tops Estimate, Contraction In Manufacturing Worsens: &#8216;Reacceleration Of Inflation&#8217;</a></strong></p>
<h2 class="wp-block-heading">How To Buy WFC Stock</h2>
<p>By now you're likely curious about how to participate in the market for Wells Fargo &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.</p>
<p>In the the case of Wells Fargo, which is trading at $55.21 as of publishing time, $100 would buy you 1.81 shares of stock.</p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WFC has a 52-week high of $62.55 and a 52-week low of $38.38.</p>


What's Going On With Wells Fargo (WFC) Stock?

Boeing Increases General Wage By 30%, Boosts 401(K) Match To 100% Of First 8% Of Pay, And Raises Ratification Bonus To $6,000 In IAM Labor Negotiations

<p><strong>Corbus Pharmaceuticals Holdings, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) received reaffirmed buy ratings from both <strong>H.C. Wainwright</strong> and <strong>Oppenheimer</strong> this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a <a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d">sharp stock decline</a> after <strong>Novo Nordisk</strong>&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) mid-stage data on its obesity drug.</p>
<p><strong>Andres Maldonado</strong> of H.C. Wainwright reiterated a Buy rating for Corbus with an $80 price target, highlighting that Novo's recent challenges with monlunabant, a drug targeting the same receptor as Corbus&#8217; <strong>CRB-913</strong>, should not impact the latter's potential. The stock currently trades below the $20 mark.</p>
<p>Maldonado<a href="https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-corbus-pharmaceuticals-on-crb-913s-potential-and-holistic-pipeline-valuation?utm_source=benzinga.com&amp;utm_medium=referral"> stressed </a>that different drugs within the same class could exhibit unique efficacy and safety profiles.&nbsp;</p>
<ul>
<li><strong><em>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</em></strong></li>
</ul>
<h3 class="wp-block-heading">Oppenheimer And Mizuho Double Down On Corbus' Pipeline</h3>
<p>Oppenheimer also maintained a Buy rating, setting a price target of $88, focusing not only on CRB-913 but also on Corbus' broader assets, especially CRB-701.&nbsp;</p>
<p>Mizuho similarly recommended <a href="https://seekingalpha.com/news/4151904-mizuho-recommends-buying-corbus-following-its-drop-post-novos-obesity-data?utm_source=partner_&amp;utm_medium=referral&amp;feed_item_type=news">buying the dip</a>, viewing the recent 60% stock plunge as an overreaction.&nbsp;</p>
<p>The firm pointed to CRB-701's positive Phase 1 data and sees the company's valuation primarily tied to this Nectin-4-based ADC for cancer treatment, rather than the obesity drug alone.</p>
<p><strong>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d">Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk&#8217;s Cannabinoid-Based Weight Loss Drug Trial Disappoints</a></strong></p>


Cannabis

Price Target

Reiteration

CRBP

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Centene's Health Net Subsidiary Selected For California Medicaid Dental Contract In Los Angeles And Sacramento Counties, Starting July 2025

<p>Piper Sandler  analyst Joseph Catanzaro   maintains Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) with a Overweight and raises the price target from $12 to $15.</p>


BDTX

Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Raises Price Target to $15

<p>Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $103.19, a high estimate of $123.00, and a low estimate of $80.00. This upward trend is evident, with the current average reflecting a 12.99% increase from the previous average price target of $91.33.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114456_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Best Buy Co is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$116.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$123.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$107.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Elizabeth Suzuki</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Best Buy Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Best Buy Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Best Buy Co's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Best Buy Co's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BBY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Best Buy Co analyst ratings.</strong></a></p>
<h2>Delving into Best Buy Co's Background</h2>
<p>With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.</p>
<h3>Best Buy Co: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Challenges:</strong> Best Buy Co's revenue growth over 3 months faced difficulties. As of 31 July, 2024, the company experienced a decline of approximately <strong>-3.08%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Best Buy Co's net margin excels beyond industry benchmarks, reaching <strong>3.13%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Best Buy Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>9.4%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Best Buy Co's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.92%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Best Buy Co's debt-to-equity ratio is below the industry average at <strong>1.32</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 16 Analyst Evaluations For Best Buy Co

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>United Parcel Service</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with UPS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for United Parcel Service.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $271,854, and 5 are calls, for a total amount of $313,243.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $110.0 to $145.0 for United Parcel Service over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for United Parcel Service's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United Parcel Service's whale activity within a strike price range from $110.0 to $145.0 in the last 30 days. </p>
<h3>United Parcel Service 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114455_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.9</td>
<td>$6.75</td>
<td>$6.9</td>
<td>$140.00</td>
<td>$96.6K</td>
<td>899</td>
<td>142</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$1.15</td>
<td>$0.96</td>
<td>$0.96</td>
<td>$145.00</td>
<td>$82.4K</td>
<td>2.7K</td>
<td>2.2K</td>
</tr>
<tr>
<td>UPS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$130.00</td>
<td>$75.0K</td>
<td>1.6K</td>
<td>151</td>
</tr>
<tr>
<td>UPS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$19.25</td>
<td>$18.85</td>
<td>$19.25</td>
<td>$135.00</td>
<td>$67.3K</td>
<td>904</td>
<td>45</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$0.98</td>
<td>$0.97</td>
<td>$0.98</td>
<td>$145.00</td>
<td>$59.0K</td>
<td>2.7K</td>
<td>882</td>
</tr>
</tbody>
</table>
</p>
<h3>About United Parcel Service</h3>
<p>As the world's largest parcel delivery company, UPS manages a massive fleet of more than 500 planes and 100,000 vehicles, along with many hundreds of sorting facilities, to deliver an average of about 22 million packages per day to residences and businesses across the globe. UPS' domestic US package operations generate around 64% of total revenue while international package makes up 20%. Air and ocean freight forwarding, truckload brokerage, and contract logistics make up the remainder. UPS is currently pursuing "strategic alternatives" for its truck brokerage unit, Coyote, which it acquired in 2015.</p>
<p>Having examined the options trading patterns of United Parcel Service, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>United Parcel Service's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,534,525, the price of UPS is up by 0.14%, reaching $128.78.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 31 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest United Parcel Service options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Smart Money Is Betting Big In UPS Options

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>AutoZone</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AZO, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for AutoZone.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 20% bullish and 53%, bearish.</p>
<p>Out of all of the special options we uncovered, 10 are puts, for a total amount of $464,107, and 5 are calls, for a total amount of $219,793.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $2650.0 to $3700.0 for AutoZone over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AutoZone's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AutoZone's whale trades within a strike price range from $2650.0 to $3700.0 in the last 30 days. </p>
<h3>AutoZone Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114450_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$36.0</td>
<td>$35.0</td>
<td>$36.0</td>
<td>$2900.00</td>
<td>$86.4K</td>
<td style="text-align: right;">23</td>
<td style="text-align: right;">81</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$77.9</td>
<td>$68.0</td>
<td>$73.71</td>
<td>$3300.00</td>
<td>$73.7K</td>
<td style="text-align: right;">33</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$678.6</td>
<td>$662.0</td>
<td>$678.2</td>
<td>$3700.00</td>
<td>$67.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$88.6</td>
<td>$82.1</td>
<td>$84.0</td>
<td>$3040.00</td>
<td>$58.8K</td>
<td style="text-align: right;">18</td>
<td style="text-align: right;">19</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$93.9</td>
<td>$87.1</td>
<td>$93.9</td>
<td>$3060.00</td>
<td>$56.3K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
</tr>
</tbody>
</table>
</p>
<h3>About AutoZone</h3>
<p>AutoZone operates as a leading retailer of aftermarket automotive parts in the United States. The firm operates over 6,300 stores domestically, serving both the do-it-yourself and commercial (do-it-for-me) end markets. Through its vast store footprint and distribution network, AutoZone manages a wide array of stock-keeping units applicable to numerous vehicle makes and models, providing its consumers with ample product availability. The firm drives traffic by providing superior and convenient customer service as AutoZone's team of knowledgeable staff assists consumers with diagnosing a vehicle's problem, selecting the necessary part for replacement, and in some instances, installation. The company also operates internationally, with over 750 stores in Mexico and more than 100 in Brazil.</p>
<h3>AutoZone's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 71,303, the AZO's price is up by 0.73%, now at $3042.63. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>Expert Opinions on AutoZone</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $3275.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for AutoZone, targeting a price of $3350.<br />
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $3200. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for AutoZone, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AutoZone Unusual Options Activity

<p>Investors with significant funds have taken a bullish position in Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>), a development that retail traders should be aware of.</p>
<p>This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in CRBP usually indicates foreknowledge of upcoming events.</p>
<p>Today, Benzinga's options scanner identified 12 options transactions for Corbus Pharmaceuticals. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 50% being bullish and 25% bearish. Of all the options we discovered, 11 are puts, valued at $389,510, and there was a single call, worth $52,400.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $17.5 and $55.0 for Corbus Pharmaceuticals, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Corbus Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Corbus Pharmaceuticals's significant trades, within a strike price range of $17.5 to $55.0, over the past month.</p>
<h3>Corbus Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114445_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRBP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$2.25</td>
<td>$2.6</td>
<td>$30.00</td>
<td>$52.4K</td>
<td>12</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$31.6</td>
<td>$30.3</td>
<td>$30.9</td>
<td>$50.00</td>
<td>$46.3K</td>
<td>2.2K</td>
<td style="text-align: right;">185</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$30.9</td>
<td>$30.4</td>
<td>$30.9</td>
<td>$50.00</td>
<td>$43.2K</td>
<td>2.2K</td>
<td style="text-align: right;">226</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.0</td>
<td>$2.0</td>
<td>$2.0</td>
<td>$17.50</td>
<td>$41.8K</td>
<td>0</td>
<td style="text-align: right;">47</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$31.8</td>
<td>$30.3</td>
<td>$30.6</td>
<td>$50.00</td>
<td>$36.7K</td>
<td>2.2K</td>
<td style="text-align: right;">261</td>
</tr>
</tbody>
</table>
</p>
<h3>About Corbus Pharmaceuticals</h3>
<p>Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.</p>
<p>Following our analysis of the options activities associated with Corbus Pharmaceuticals, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Corbus Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 2,140,401, the CRBP's price is down by -2.77%, now at $18.97. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 43 days.</li>
</ul>
<h3>Professional Analyst Ratings for Corbus Pharmaceuticals</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $67.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from B. Riley Securities continues to hold a Buy rating for Corbus Pharmaceuticals, targeting a price of $40.<br />
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $82.<br />
&#x2A; Consistent in their evaluation, an analyst from Wedbush keeps a Outperform rating on Corbus Pharmaceuticals with a target price of $51.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $82.<br />
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $80.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Corbus Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Spotlight on Corbus Pharmaceuticals: Analyzing the Surge in Options Activity

<p>Ratings for Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) were provided by 28 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">14</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $920.14, a high estimate of $975.00, and a low estimate of $780.00. Surpassing the previous average price target of $886.88, the current average has increased by 3.75%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114443_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Costco Wholesale is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$950.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniela Nedialkova</td>
<td>Redburn Atlantic</td>
<td>Raises</td>
<td>Neutral</td>
<td>$890.00</td>
<td>$860.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$950.00</td>
<td>$855.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$975.00</td>
<td>$970.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$915.00</td>
<td>$910.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$780.00</td>
<td>$780.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$915.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$955.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$950.00</td>
<td>$875.00</td>
</tr>
<tr>
<td>Chuck Grom</td>
<td>Gordon Haskett</td>
<td>Announces</td>
<td>Buy</td>
<td>$925.00</td>
<td>-</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$927.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$915.00</td>
<td>$920.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$925.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>George Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$800.00</td>
<td>$775.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$950.00</td>
<td>$905.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$920.00</td>
<td>$890.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$830.00</td>
<td>$765.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$970.00</td>
<td>$940.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$950.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$962.00</td>
<td>$874.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$975.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$900.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$850.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Costco Wholesale. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Costco Wholesale compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Costco Wholesale's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Costco Wholesale's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/COST/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Costco Wholesale analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Costco Wholesale</h2>
<p>Costco operates a membership-based, no-frills retail model, predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given Costco's frugal cost structure, the firm is able to price its merchandise below competing retailers, driving high sales volume per warehouse and allowing the retailer to generate strong profits on thin margins. Costco operates over 600 warehouses in the United States and enjoys over 60% market share in the domestic warehouse club industry. Internationally, Costco operates another 270 warehouses, primarily in markets such as Canada, Mexico, Japan, and the UK.</p>
<h3>Financial Milestones: Costco Wholesale's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Costco Wholesale showcased positive performance, achieving a revenue growth rate of <strong>9.07%</strong> as of 31 May, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Costco Wholesale's net margin is impressive, surpassing industry averages. With a net margin of <strong>2.87%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Costco Wholesale's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.9%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Costco Wholesale's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.5%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.43</strong>, Costco Wholesale adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


COST

Demystifying Costco Wholesale: Insights From 28 Analyst Reviews

<p>In the last three months, 11 analysts have published ratings on EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.73, a high estimate of $6.00, and a low estimate of $4.00. Observing a 2.83% increase, the current average has risen from the previous average price target of $4.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114434_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive EVgo. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>William Grippin</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$4.00</td>
<td>-</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Michael Legg</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$5.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to EVgo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EVgo compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for EVgo's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of EVgo's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EVGO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on EVgo analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know EVgo Better</h2>
<p>EVgo owns and operates a public direct current fast-charging network in the us. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the us. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments and independent property owners in order to locate and deploy its EV charging infrastructure.</p>
<h3>Key Indicators: EVgo's Financial Health</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> EVgo's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>31.78%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> EVgo's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-15.47%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> EVgo's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-52.49%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> EVgo's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-1.31%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> EVgo's debt-to-equity ratio is below the industry average. With a ratio of <b>5.86</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EVGO

Analyst Scoreboard: 11 Ratings For EVgo

<p>16 analysts have shared their evaluations of Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Home Depot and provided 12-month price targets. The average target is $384.31, accompanied by a high estimate of $430.00 and a low estimate of $330.00. Surpassing the previous average price target of $377.86, the current average has increased by 1.71%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114427_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Home Depot is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$420.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$360.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$430.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$363.00</td>
<td>$377.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$330.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$395.00</td>
<td>$396.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$425.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$375.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$377.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$396.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$380.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Buy</td>
<td>$395.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Home Depot. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Home Depot compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Home Depot's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Home Depot's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Home Depot analyst ratings.</strong></a></p>
<h2>Delving into Home Depot's Background</h2>
<p>Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The additions of the Company Store brought textiles to the lineup, and Redi Carpet added multifamily flooring, while the recent tie-up with SRS will help grow professional demand.</p>
<h3>Home Depot: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Home Depot's remarkable performance in 3 months is evident. As of 31 July, 2024, the company achieved an impressive revenue growth rate of <strong>0.6%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Home Depot's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>10.56%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Home Depot's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>146.19%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Home Depot's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.18%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>14.62</strong>, Home Depot faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Home Depot Through 16 Analysts

<p><strong>Constellation Energy Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) shares are trading relatively flat today after jumping more than 22% after the company signed a 20-year <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40957437/microsoft-taps-constellation-for-20-year-carbon-free-power-3-400-jobs-coming-to-pennsylvania" rel="noreferrer noopener">power purchase agreement with </a><strong><a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40957437/microsoft-taps-constellation-for-20-year-carbon-free-power-3-400-jobs-coming-to-pennsylvania" rel="noreferrer noopener">Microsoft </a></strong><a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40957437/microsoft-taps-constellation-for-20-year-carbon-free-power-3-400-jobs-coming-to-pennsylvania" rel="noreferrer noopener">on Friday.</a></p>
<p>The deal entails the launch of the Crane Clean Energy Center (CCEC) and the restart of Three Mile Island Unit 1,&nbsp;which was closed five years ago.</p>
<p>Following the announcement, several analysts raised the price target on the stock.</p>
<p><strong>KeyBanc </strong>analyst Sophie Karp maintained an Overweight rating and raised <a target="_blank" href="https://www.benzinga.com/quote/CEG/analyst-ratings" rel="noreferrer noopener">the price target from&nbsp;$230&nbsp;to&nbsp;$265</a>.</p>
<p>The analyst writes that the deal allows for reevaluating other parts of CEG&#8217;s portfolio, and they expect continued positive momentum for the shares.</p>
<p>Nuclear generation has unique scarcity characteristics that are difficult to replicate at scale, positioning CEG to leverage its asset base and expertise as the country&#8217;s largest nuclear operator, says the analyst.</p>
<p>Although the company did not disclose the offtake price, Karp estimates that it needs to be around $120/MWh to achieve a projected increase in &#8220;base&#8221; EPS CAGR from 10% to 13% between 2024 and 2030.</p>
<p>The analyst writes that the price is a significant premium over current PJM power curves and exceeds the estimated ~$60/MWh gross receipts from CEG&#8217;s PJM fleet based on recent capacity pricing.</p>
<p>The analyst updated the estimates based on the second-quarter results, revised power and capacity prices, and operating assumptions.</p>
<p>The impacts of the MSFT deal will be outside the forecast horizon, as the plant is expected to restart in 2028, adds the analyst.</p>
<p>Apart from this, <strong>Evercore ISI</strong> maintained an Outperform rating, with an increased price target to $254 from $212.</p>
<p>Maintaining an Overweight rating, <strong>Wells Fargo </strong>increased the price target to&nbsp;$300 from $250 and <strong>Morgan Stanley</strong> to $313 from $233.</p>
<p>Investors can gain exposure to the stock via&nbsp;<strong>Strive Natural Resources and Security ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTWO#NYSE">FTWO</a>) and&nbsp;<strong>Virtus Reaves Utilities ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTES#NYSE">UTES</a>).</p>
<p><strong>Price Action</strong>: CEG shares are down 0.12% at $254.69 at the last check Monday.</p>
<p><em>Photo by metamorworks via Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com//node/40986267" target="_blank" rel="noreferrer noopener">GE Aerospace Takes Flight With AI Wingmate: Boosts Innovation, Employee Productivity With Microsoft&#8217;s Azure AI</a></strong></li>
</ul>


Analyst Color

Equities

Large Cap

FTWO

UTES

Constellation Energy's Microsoft Deal Sparks Long-Term Growth: Analysts Raise Price Forecasts Amid Nuclear Revival

<p>Ratings for Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $209.0, a high estimate of $250.00, and a low estimate of $160.00. Observing a downward trend, the current average is 7.49% lower than the prior average price target of $225.91. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114418_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Atlassian by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$175.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$177.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Connor Murphy</td>
<td>Capital One</td>
<td>Announces</td>
<td>Overweight</td>
<td>$211.00</td>
<td>-</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Atlassian. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Atlassian compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Atlassian's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Atlassian's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TEAM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Atlassian analyst ratings.</strong></a></p>
<h2>Discovering Atlassian: A Closer Look</h2>
<p>Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.</p>
<h3>Atlassian's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Atlassian's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>20.5%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Atlassian's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-17.4%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Atlassian's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-18.17%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Atlassian's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-3.83%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Atlassian's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.21</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TEAM

Analyst Scoreboard: 12 Ratings For Atlassian

<p>Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) has outperformed the market over the past 20 years by 21.31% on an annualized basis producing an average annual return of 29.79%. Currently, Booking Holdings has a market capitalization of $136.24 billion. </p>
<p><strong>Buying $100 In BKNG:</strong> If an investor had bought $100 of BKNG stock 20 years ago, it would be worth <strong>$18,428.06</strong> today based on a price of $4064.00 for BKNG at the time of writing.</p>
<h3>Booking Holdings's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114417_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BKNG

$100 Invested In Booking Holdings 20 Years Ago Would Be Worth This Much Today

<p>Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) has outperformed the market over the past 10 years by 7.2% on an annualized basis producing an average annual return of 18.39%. Currently, Visa has a market capitalization of $561.38 billion. </p>
<p><strong>Buying $100 In V:</strong> If an investor had bought $100 of V stock 10 years ago, it would be worth <strong>$547.08</strong> today based on a price of $288.50 for V at the time of writing.</p>
<h3>Visa's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114412_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In Visa 10 Years Ago Would Be Worth This Much Today

<p>Analysts' ratings for Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $50.57, along with a high estimate of $58.00 and a low estimate of $39.00. Marking an increase of 7.14%, the current average surpasses the previous average price target of $47.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114409_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Tandem Diabetes Care among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Tandem Diabetes Care's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Tandem Diabetes Care's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Tandem Diabetes Care analyst ratings.</strong></a></p>
<h2>About Tandem Diabetes Care</h2>
<p>Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.</p>
<h3>Key Indicators: Tandem Diabetes Care's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Tandem Diabetes Care displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>13.27%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Tandem Diabetes Care's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-13.89%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Tandem Diabetes Care's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-12.92%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-3.28%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Tandem Diabetes Care's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>2.04</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TNDM

Analyst Scoreboard: 7 Ratings For Tandem Diabetes Care

<p>Piper Sandler  analyst Christopher Raymond   maintains Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) with a Overweight and raises the price target from $66 to $76.</p>


BHVN

Piper Sandler Maintains Overweight on Biohaven, Raises Price Target to $76

Baosheng Media Group Holdings Ltd (BAOS) stock is lower by -27.16% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives BAOS stock a score of  13 out of a possible 100. That rank is chiefly influenced by a long-term technical score of 14. BAOS's rank also includes a short-term technical score of 2

Should You Buy Baosheng Media Group Holdings Ltd (BAOS) Stock Tuesday?

IMAX, CPOP among major communication services gainers; IAS, SSP among losers

The market has been high on Baosheng Media Group Holdings Ltd (BAOS)  stock recently. BAOS gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Baosheng Media Group Holdings Ltd has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BAOS!See Full BAOS ReportW

Should You Buy Baosheng Media Group Holdings Ltd (BAOS) Stock on Thursday?

Baosheng Media Group Holdings Ltd (BAOS) has released an update. Baosheng Media Group Holdings Ltd is facing a lawsuit from three institutional inv...

Baosheng Media Confronts Investor Lawsuit

PARA, AMC among major communication services gainers; NFLX, TC among losers

Baosheng Media Group Holdings Ltd (BAOS) has released an update. Baosheng Media Group Holdings Ltd is currently facing a legal challenge as Orient ...

Baosheng Media Confronts Shareholder Lawsuit

Baosheng Media Group Holdings Ltd (BAOS) has released an update. Baosheng Media Group Holdings Ltd faces a significant legal challenge as a petitio...

Baosheng Media Grapples with Liquidation Petition

CMCM, BZFD among major communication services gainers; MDIA, IHRT among losers

KUKE, FENG among major communication services gainers; CCG, MSGM among losers

Baosheng Media Group Holdings (BAOS) has released an update. Baosheng Media Group Holdings Limited has faced the termination of two significant inv...

Baosheng Media Faces Investment Deal Terminations

BZFD

CMCM

CMLS

CURI

DLPN

FENG

GSAT

IHRT

IMAX

KUKE

MCHX

MDIA

MSGM

NFLX

PARA

PGRU

UONE

WIMI

Opinion

Press Releases

Thinking about buying stock in WeTrade Group, Nio, Arista Networks, Baosheng Media, or TAL Education Group?

Baosheng Media Group Holdings Limited Announces Filing of Current Report on Form 6-K with the SEC regarding Pending Legal Proceeding

ANET

WETG

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Baosheng Media Gr

Baosheng Media Gr (BAOS) Forecast

Baosheng Media Gr (NASDAQ:BAOS) Stock, Quote.Headers.trade-ideas